AFG210
AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC50=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase[1].
Product Specifications
CAS Number
228400-22-4
UNSPSC
12352005
Target
Bcr-Abl; FGFR; Raf; RET; VEGFR
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/afg210.html
Smiles
O=C(NC1=CC=C(OC2=CC=NC=C2)C=C1)NC3=CC=CC(C(F)(F)F)=C3
Molecular Formula
C19H14F3N3O2
Molecular Weight
373.33
References & Citations
[1]AC Backes, et al. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert opinion on drug discovery, 3 (12), 1427-1449.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC741983-500 1x 500 µL
Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
RG239932 10 µg
ZFP106 (ZNF106) (NM_001284306) Human Tagged ORF Clone
Sign In for Pricing
View Details 